2003   Dec, 31 Lupin files INDA for anti-psoriasis   Dec, 5 Lupin receives IND approval for anti-migraine molecule Two Citigroup representatives join Lupin’s board   Nov, 4 Promoters sell 4% of Lupin equity   Oct, 13 Lupin promoters, Newbridge call off discussions   Oct, 11 Lupin promoters place 12.55% equity with CVC International   Oct, 10 Lupin Q2 FY 2003-04 net profit before extraordinary items at Rs.518 mn,up 86%; sales up 36% at Rs 3609 mn   Oct, 1 Lupin receives USFDA approval for ceftriaxone sterile vials for injection   Sept, 25 Lupin receives USFDA approval for cefotaxime sterile vials for injection   Aug, 25 Dr. Kamal K. Sharma to join Lupin as Managing Director   July, 31 Lupin Q1 FY 2003-04 net profit up 38% at Rs 280.6 mn; sales up 23% at Rs 2,769 mn   July, 28 Lupin receives USFDA approval for cefuroxime axetil tablets   May, 20 Lupin FY2002-03 net sales up 19% at Rs 10.3 bn   May, 9 Lupin launches once-a-day dosage cephalexin   April, 17 Statement on media reports linking SARS outbreak with demand for Lupin's ribavirin   April, 16 Lupin files ANDAs for Ceftriaxone and Cefotaxime   Feb, 13 Lupin to set up new Lovastatin plant A move to consolidate presence in lifestyle drugs   Jan, 28 Lupin Q3 sales up 19% at Rs. 2868 mn; net profit up 23% at Rs. 227mn